RU2499795C2 - Антагонисты гистаминовых н3-рецепторов - Google Patents
Антагонисты гистаминовых н3-рецепторов Download PDFInfo
- Publication number
- RU2499795C2 RU2499795C2 RU2011142654/04A RU2011142654A RU2499795C2 RU 2499795 C2 RU2499795 C2 RU 2499795C2 RU 2011142654/04 A RU2011142654/04 A RU 2011142654/04A RU 2011142654 A RU2011142654 A RU 2011142654A RU 2499795 C2 RU2499795 C2 RU 2499795C2
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- isopropylpiperazin
- phenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Изобретение относится к новым соединениям, которые взаимодействуют с Н3-гистаминовым рецептором и содержат в своей структуре пиридиновое кольцо. Кроме того, изобретение относится к фармацевтической композиции для модуляции Н3-гистаминовых рецепторов, содержащей соединения, описанные выше. Технический результат: описанные соединения являются полезными в лечении ряда заболеваний или состояний, при которых взаимодействия с Н3-гистаминовым рецептором являются благоприятными, таким образом, данные соединения могут найти применение, например, в лечении заболеваний центральной нервной системы, периферической нервной системы, сердечно-сосудистой системы, пульмональной системы, желудочно-кишечного тракта и эндокринной системы. 2 н. и 7 з.п. ф-лы, 216 пр.
Description
Claims (9)
1. Соединение, которое выбрано из группы, включающей в себя:
N-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}ацетамид;
N-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}ацетамид;
4-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}морфолин;
N,N-Диизопропил-4-[6-(4-изопропилпиперазин-1-ил)пиридин-3-ил]бензамид;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперидин-1-ил)метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}морфолин-4-илметанон;
4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]-N,N-диметилбензамид;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}пиперидин-1-илметанон;
(4-Гидроксиметилпиперидин-1-ил)-{4-[6-(4-изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперазин-1-ил)метанон;
{4-[6-(4-Циклопропилпиперазин-1-ил)пиридин-3-ил]фенил}пиперидин-1-илметанон;
{4-[6-(4-Циклопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперазин-1-ил)метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метоксиметилпиперидин-1-ил)-метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}диметиламин;
1-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}-4-метилпиперазин;
(1-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}пиперидин-4-ил)метанол;
1-Изопропил-4-[5-(4-пиперидин-1-илметилфенил)пиридин-2-ил]пиперазин;
1-Циклопропил-4-[5-(4-пиперидин-1-илметилфенил)пиридин-2-ил]пиперазин;
или его фармацевтически приемлемая соль.
N-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}ацетамид;
N-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}ацетамид;
4-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}морфолин;
N,N-Диизопропил-4-[6-(4-изопропилпиперазин-1-ил)пиридин-3-ил]бензамид;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперидин-1-ил)метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}морфолин-4-илметанон;
4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]-N,N-диметилбензамид;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}пиперидин-1-илметанон;
(4-Гидроксиметилпиперидин-1-ил)-{4-[6-(4-изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперазин-1-ил)метанон;
{4-[6-(4-Циклопропилпиперазин-1-ил)пиридин-3-ил]фенил}пиперидин-1-илметанон;
{4-[6-(4-Циклопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперазин-1-ил)метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метоксиметилпиперидин-1-ил)-метанон;
{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}диметиламин;
1-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}-4-метилпиперазин;
(1-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}пиперидин-4-ил)метанол;
1-Изопропил-4-[5-(4-пиперидин-1-илметилфенил)пиридин-2-ил]пиперазин;
1-Циклопропил-4-[5-(4-пиперидин-1-илметилфенил)пиридин-2-ил]пиперазин;
или его фармацевтически приемлемая соль.
2. Соединение по п.1, которое представляет собой N-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}ацетамид или его фармацевтически приемлемую соль.
3. Соединение по п.1, которое представляет собой N-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}ацетамид или его фармацевтически приемлемую соль.
4. Соединение по п.1, которое представляет собой 4-{4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]бензил}морфолин или его фармацевтически приемлемую соль.
5. Соединение по п.1, которое представляет собой N,N-Диизопропил-4-[6-(4-изопропилпиперазин-1-ил)пиридин-3-ил]бензамид или его фармацевтически приемлемую соль.
6. Соединение по п.1, которое представляет собой {4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}-(4-метилпиперидин-1-ил)метанон или его фармацевтически приемлемую соль.
7. Соединение по п.1, которое представляет собой {4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]фенил}морфолин-4-илметанон или его фармацевтически приемлемую соль.
8. Соединение по п.1, которое представляет собой 4-[6-(4-Изопропилпиперазин-1-ил)пиридин-3-ил]-N,N-диметилбензамид или его фармацевтически приемлемую соль.
9. Фармацевтическая композиция для модуляции Н3-гистаминовых рецепторов, содержащая соединение по любому из пп.1-8 и фармацевтически приемлемый носитель или эксципиент.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05106038.2 | 2005-07-04 | ||
EP05106037 | 2005-07-04 | ||
EP05106038 | 2005-07-04 | ||
EP05106037.4 | 2005-07-04 | ||
EP05109674 | 2005-10-18 | ||
EP05109674.1 | 2005-10-18 | ||
EP06114615.5 | 2006-05-29 | ||
EP06114615 | 2006-05-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007147044/04A Division RU2442775C2 (ru) | 2005-07-04 | 2006-06-30 | Антагонисты гистаминовых н3-рецепторов |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011142654A RU2011142654A (ru) | 2013-04-27 |
RU2499795C2 true RU2499795C2 (ru) | 2013-11-27 |
Family
ID=37198852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011142654/04A RU2499795C2 (ru) | 2005-07-04 | 2006-06-30 | Антагонисты гистаминовых н3-рецепторов |
Country Status (13)
Country | Link |
---|---|
US (2) | US8501739B2 (ru) |
EP (3) | EP2386554A1 (ru) |
JP (1) | JP5121707B2 (ru) |
KR (1) | KR101286569B1 (ru) |
CN (1) | CN103110635A (ru) |
AT (1) | ATE536344T1 (ru) |
AU (1) | AU2006264966B2 (ru) |
BR (1) | BRPI0613564A2 (ru) |
CA (1) | CA2614116A1 (ru) |
ES (1) | ES2375929T3 (ru) |
MX (1) | MX2007015675A (ru) |
RU (1) | RU2499795C2 (ru) |
WO (1) | WO2007003604A2 (ru) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
EP2386554A1 (en) | 2005-07-04 | 2011-11-16 | High Point Pharmaceuticals, LLC | Compounds active at the histamine H3 receptor |
GB0525957D0 (en) * | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
EA016264B1 (ru) | 2006-03-31 | 2012-03-30 | Янссен Фармацевтика Н.В. | Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н |
CA2653062A1 (en) * | 2006-05-23 | 2007-11-29 | Transtech Pharma, Inc. | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
ATE538116T1 (de) * | 2006-05-29 | 2012-01-15 | High Point Pharmaceuticals Llc | 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist |
AU2007260836B2 (en) | 2006-06-23 | 2012-11-15 | Abbvie Bahamas Ltd. | Cyclopropyl amine derivatives as histamin H3 receptor modulators |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
TW200901998A (en) * | 2007-03-06 | 2009-01-16 | Astrazeneca Ab | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes |
US8653262B2 (en) | 2007-05-31 | 2014-02-18 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists and uses thereof |
EP2014656A3 (en) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
ES2479440T3 (es) * | 2008-01-30 | 2014-07-24 | Cephalon, Inc. | Derivados de piridazina sustituidos que tienen actividad antagonista de histamina H3 |
MY172105A (en) | 2008-05-14 | 2019-11-14 | Scripps Research Inst | Novel modulators of sphingosine phosphate receptors |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
US8193363B2 (en) | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
EA020548B1 (ru) | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
AR076126A1 (es) | 2009-03-18 | 2011-05-18 | Schering Corp | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
WO2011034078A1 (ja) * | 2009-09-16 | 2011-03-24 | アステラス製薬株式会社 | グリシン化合物 |
PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
EP2569294B1 (en) * | 2010-05-11 | 2015-03-11 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
EP2576542B1 (en) | 2010-05-25 | 2015-04-22 | Boehringer Ingelheim International GmbH | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases |
JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2アンタゴニスト |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
PL2964229T3 (pl) | 2013-03-06 | 2020-05-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-ilo pirymidynowe modulatory receptora histaminowego H<sub>4</sub> |
GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
KR102318727B1 (ko) | 2013-07-31 | 2021-10-28 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
EP3053577A1 (en) * | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
JP6884102B2 (ja) | 2015-02-09 | 2021-06-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための化合物 |
BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
EP3373935B1 (en) * | 2015-11-12 | 2021-09-01 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
PL3386511T3 (pl) * | 2015-12-10 | 2021-11-08 | Ptc Therapeutics, Inc. | Sposoby leczenia choroby huntingtona |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
MX2019014514A (es) | 2017-06-05 | 2020-07-20 | Ptc Therapeutics Inc | Compuestos para tratar la enfermedad de huntington. |
CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
FI3814357T3 (fi) | 2018-06-27 | 2024-07-26 | Ptc Therapeutics Inc | Heterosykliset ja heteroaryliyhdisteet huntingtonin taudin hoitoon |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
BR112022004811A2 (pt) | 2019-09-17 | 2022-06-21 | Boston Polarimetrics Inc | Sistemas e métodos para modelagem de superfície usando indicações de polarização |
BR112022006617A2 (pt) | 2019-10-07 | 2022-06-28 | Boston Polarimetrics Inc | Sistemas e métodos para detecção por sensor de normais à superfície com polarização |
CA3162710A1 (en) | 2019-11-30 | 2021-06-03 | Boston Polarimetrics, Inc. | Systems and methods for transparent object segmentation using polarization cues |
US11195303B2 (en) | 2020-01-29 | 2021-12-07 | Boston Polarimetrics, Inc. | Systems and methods for characterizing object pose detection and measurement systems |
WO2021154459A1 (en) | 2020-01-30 | 2021-08-05 | Boston Polarimetrics, Inc. | Systems and methods for synthesizing data for training statistical models on different imaging modalities including polarized images |
WO2021243088A1 (en) | 2020-05-27 | 2021-12-02 | Boston Polarimetrics, Inc. | Multi-aperture polarization optical systems using beam splitters |
WO2022053541A1 (en) * | 2020-09-10 | 2022-03-17 | Eracal Therapeutics Ltd. | Compounds for use as appetite suppressant |
US12020455B2 (en) | 2021-03-10 | 2024-06-25 | Intrinsic Innovation Llc | Systems and methods for high dynamic range image reconstruction |
US11954886B2 (en) | 2021-04-15 | 2024-04-09 | Intrinsic Innovation Llc | Systems and methods for six-degree of freedom pose estimation of deformable objects |
US11290658B1 (en) | 2021-04-15 | 2022-03-29 | Boston Polarimetrics, Inc. | Systems and methods for camera exposure control |
US11689813B2 (en) | 2021-07-01 | 2023-06-27 | Intrinsic Innovation Llc | Systems and methods for high dynamic range imaging using crossed polarizers |
WO2023034836A1 (en) * | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
CN114478478B (zh) * | 2022-02-18 | 2023-06-13 | 厦门大学 | N-(1-(6-(取代苯基)哒嗪-3-基)哌啶-3-基)胺/酰胺衍生物及制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1345880A (en) * | 1971-06-18 | 1974-02-06 | Cepbepe | Pyridazine derivatives |
US3886161A (en) * | 1970-12-14 | 1975-05-27 | Sandoz Ag | 2-Piperazino-3-cyano-5-phenyl-pyridines |
DE2824764A1 (de) * | 1978-06-06 | 1979-12-20 | Hoechst Ag | Neue pyridylpiperazinderivate und verfahren zu ihrer herstellung |
US4251658A (en) * | 1977-06-13 | 1981-02-17 | Richter Gedeon Vegyeszeti Gyar Rt. | 3-(1-Pyrazolyl)-pyridazine derivatives |
US4616014A (en) * | 1981-10-22 | 1986-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
EA005160B1 (ru) * | 2001-07-12 | 2004-12-30 | Ле Лаборатуар Сервье | НОВЫЕ СОЕДИНЕНИЯ ОКТАГИДРО-2H-ПИРИДО[1,2-α]ПИРАЗИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ИХ СОДЕРЖАЩИЕ |
WO2005028438A1 (ja) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB753166A (en) | 1953-05-22 | 1956-07-18 | Miles Lab | Improvements in or relating to substituted piperazines |
US2724713A (en) | 1954-03-24 | 1955-11-22 | American Cyanamid Co | 1-carbobenzoxypiperazines and process of preparing same |
US2993899A (en) | 1958-03-31 | 1961-07-25 | Miles Lab | Acetylenically unsaturated piperazine derivatives |
US3164598A (en) | 1963-02-01 | 1965-01-05 | American Home Prod | Substituted 1, 4-diazabicyclo[4.3.0]nonanes and methods for their preparation |
US3309370A (en) | 1964-07-16 | 1967-03-14 | Miles Lab | Bicycloalkyl piperazine derivatives and process |
GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
DE2516040C2 (de) | 1974-06-10 | 1984-12-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
FR2306694A1 (fr) | 1975-04-07 | 1976-11-05 | Parcor | Derives de la piperazine |
GB1545094A (en) | 1976-12-14 | 1979-05-02 | Gist Brocades Nv | Piperazine derivatives |
US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
US4163849A (en) | 1978-03-17 | 1979-08-07 | Merck & Co., Inc. | Piperazinylpyrazines |
DE3160397D1 (en) | 1980-02-22 | 1983-07-14 | Tanabe Seiyaku Co | Phenoxyalkane derivative and processes for preparing same |
US4339579A (en) | 1980-12-29 | 1982-07-13 | American Home Products Corporation | 2,6-Bis-(pyrrolopyrazinyl)pyrazines |
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
FR2573075B1 (fr) | 1984-09-14 | 1987-03-20 | Innothera Lab Sa | Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique |
DE3526235A1 (de) | 1984-11-16 | 1986-05-22 | Bayer Ag, 5090 Leverkusen | Fluessigkristallzusammensetzungen |
EP0204003A4 (en) | 1984-11-27 | 1987-06-03 | Dainippon Pharmaceutical Co | 2- (1-PIPERAZINYL) -4-SUBSTITUTED PHENYLQUINOLINE SCRUBBINGS. |
EP0200024B1 (de) | 1985-04-30 | 1992-07-01 | ARZNEIMITTELWERK DRESDEN GmbH | 3-Cyan-pyridine, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US4670505A (en) * | 1985-08-23 | 1987-06-02 | Hercules Incorporated | Polyacrylate dispersions |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
DK111387A (da) | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
DE3609596A1 (de) | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
MY104343A (en) | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
DE3803860A1 (de) | 1988-02-09 | 1989-08-17 | Basf Ag | N,n'-disubstituierte piperazine |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
ATE107922T1 (de) | 1989-03-03 | 1994-07-15 | Dainippon Pharmaceutical Co | 2-(1-piperazinyl)-4-phenylcycloalkanpyridin- derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
EP0674627A1 (en) | 1992-12-18 | 1995-10-04 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
DE4308028B4 (de) | 1993-03-13 | 2012-08-16 | Merck Patent Gmbh | 1,2,2,2-Tetrafluorethylether und flüssigkristallines Medium |
WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
JP3377826B2 (ja) | 1993-05-06 | 2003-02-17 | ヘキスト・アクチェンゲゼルシャフト | 液晶組成物に使用するための新規化合物 |
EP0705275B1 (en) | 1993-06-21 | 1999-02-03 | Novo Nordisk A/S | Asp-b28 insulin crystals |
CN1056618C (zh) | 1993-09-17 | 2000-09-20 | 诺沃挪第克公司 | 酰化的胰岛素和含有这种胰岛素的药物组合物 |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
DE4423044A1 (de) | 1994-07-01 | 1996-01-04 | Hoechst Ag | 1-(3-Alkyloxiran-2-yl)alkylester mesogener Carbonsäuren und ihre Verwendung in flüssigkristallinen Mischungen |
DE4425642A1 (de) | 1994-07-20 | 1996-01-25 | Merck Patent Gmbh | Partiell fluorierte Benzolderivate |
AU6318896A (en) | 1995-07-06 | 1997-02-05 | Japan Tobacco Inc. | Benzamidoxime derivatives and medicinal use thereof |
US6130217A (en) | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
US5929089A (en) | 1995-11-09 | 1999-07-27 | Synthelabo | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands |
IL125071A0 (en) | 1996-01-17 | 1999-01-26 | Novo Nordisk As | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use |
EP0923580A1 (en) | 1996-07-26 | 1999-06-23 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
CN1271086C (zh) | 1996-08-30 | 2006-08-23 | 诺沃挪第克公司 | Glp-1衍生物 |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
IL127296A (en) | 1996-12-31 | 2003-01-12 | Reddy Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
EP0981526B1 (en) | 1997-05-02 | 2004-02-25 | Dr. Reddy's Laboratories Ltd. | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
JP2003514508A (ja) | 1997-07-01 | 2003-04-15 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン拮抗剤/逆作用剤 |
KR20010021936A (ko) | 1997-07-16 | 2001-03-15 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용 |
WO1999004390A1 (fr) | 1997-07-17 | 1999-01-28 | Sony Corporation | Support d'enregistrement magnetique et dispositif d'enregistrement/de reproduction magnetique le comprenant |
ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO1999021845A2 (en) | 1997-10-27 | 1999-05-06 | Agouron Pharmaceuticals, Inc. | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
ATE212991T1 (de) | 1997-12-02 | 2002-02-15 | Reddy Research Foundation | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften |
EP0978512A1 (en) | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
EP1123279A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023445A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002527502A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの調製及び使用 |
EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023417A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002527501A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、その製造及び利用 |
WO2000037474A1 (en) | 1998-12-18 | 2000-06-29 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
AU3957800A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate |
CZ20013711A3 (cs) | 1999-04-16 | 2002-07-17 | Dr. Reddy's Research Foundation | Nové polymorfní formy antidiabetických činidel, způsob jejich přípravy a farmaceutické prostředky s jejich obsahem |
AU2953699A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
BR0009864A (pt) | 1999-04-20 | 2002-01-08 | Novo Nordisk As | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto |
WO2000063190A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
AU2935200A (en) | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
DE19922723A1 (de) | 1999-05-18 | 2000-11-23 | Clariant Gmbh | Aktivmatrix-Displays mit hohem Kontrast |
DE19934799B4 (de) | 1999-07-28 | 2008-01-24 | Az Electronic Materials (Germany) Gmbh | Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten |
GB9926303D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
SK8452002A3 (en) | 1999-12-16 | 2002-11-06 | Schering Corp | Substituted 4-(phenyl or pyridyl)imidazole derivatives, pharmaceutical composition comprising the same and use thereof |
FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
AU2001249679A1 (en) | 2000-03-31 | 2001-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Phenyl-substituted imidazopyridines |
WO2001074773A2 (en) | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Phenyl-substituted indoles as histamine h3-receptor antagonists |
TR200400354T4 (tr) | 2000-03-31 | 2004-04-21 | Ortho-Mcneil Pharmaceutical, Inc. | Fenil ikameli indolizin türevleri ve bunların histamin H3 ligandları olarak kullanımı |
AU2001251083A1 (en) | 2000-03-31 | 2001-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists |
AU2001249672A1 (en) | 2000-03-31 | 2001-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Method for using 2- or 3-aryl substituted imidazo(1,2-a) pyridines as h3 antagonists |
KR100852362B1 (ko) | 2000-08-08 | 2008-08-14 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 비-이미다졸 아릴옥시피페리딘 |
US6316475B1 (en) | 2000-11-17 | 2001-11-13 | Abbott Laboratories | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications |
US20030078271A1 (en) | 2001-01-31 | 2003-04-24 | Blackburn Thomas P. | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US20030073672A1 (en) | 2001-09-05 | 2003-04-17 | Breitenbucher J. Guy | Method for treating allergies using substituted pyrazoles |
BR0307429A (pt) * | 2002-02-05 | 2004-12-28 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3 |
US20030236259A1 (en) | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
JP2003277755A (ja) | 2002-03-26 | 2003-10-02 | Fuji Photo Film Co Ltd | 液晶組成物および液晶素子 |
US6864261B2 (en) | 2002-05-02 | 2005-03-08 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
SE0201544D0 (sv) | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
JP2005529942A (ja) | 2002-06-06 | 2005-10-06 | ノボ ノルディスク アクティーゼルスカブ | 置換ピラジン類および置換アゼピン類 |
US6906060B2 (en) * | 2002-06-06 | 2005-06-14 | Novo Nordisk A/S | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines |
DE10246657A1 (de) | 2002-10-07 | 2004-04-15 | Merck Patent Gmbh | Chirales Phenolderivat, dieses enthaltendes Flüssigkristallmedium, Verfahren zur Herstellung eines Flüssigkristallmediums und elektrooptische Flüssigkristallanzeige |
US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
DE602004026068D1 (de) | 2003-07-29 | 2010-04-29 | High Point Pharmaceuticals Llc | Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden |
US20050028438A1 (en) * | 2003-08-05 | 2005-02-10 | Campana Kimberly A. | Plastic lawn edging fabricated by a continuous vacuum forming process |
US20070032477A1 (en) | 2003-10-17 | 2007-02-08 | Waer Mark J A | Pteridine derivatives useful for making pharmaceutical compositions |
WO2005046603A2 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Pyridine compounds |
FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
JP2007217282A (ja) | 2004-03-04 | 2007-08-30 | Astellas Pharma Inc | 置換ピリミジン誘導体 |
CN1942465A (zh) | 2004-04-09 | 2007-04-04 | 默克公司 | Akt活性抑制剂 |
EP1737845A4 (en) | 2004-04-13 | 2010-07-21 | Synta Pharmaceuticals Corp | DISPLAY HEMMER OF IL-12 PRODUCTION |
JP5221952B2 (ja) | 2004-05-08 | 2013-06-26 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | 3−アリール−5,6−ジ置換ピリダジン類 |
CN1956974B (zh) | 2004-05-19 | 2010-11-24 | 巴斯福股份公司 | 2-取代嘧啶及其作为农药的用途 |
CN101005842A (zh) | 2004-05-28 | 2007-07-25 | 弗特克斯药品有限公司 | 蕈毒碱性受体调节剂 |
ES2543813T3 (es) | 2004-11-02 | 2015-08-24 | Northwestern University | Compuestos de piridazina para el tratamiento de enfermedades inflamatorias |
AU2005311534B2 (en) | 2004-12-03 | 2011-02-17 | F. Hoffmann-La Roche Ag | 3-substituted pyridine derivatives as H3 antagonists |
WO2006090273A2 (en) | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
FR2885615B1 (fr) | 2005-05-12 | 2007-06-22 | Servier Lab | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2885616B1 (fr) | 2005-05-12 | 2007-06-22 | Servier Lab | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
EP2386554A1 (en) | 2005-07-04 | 2011-11-16 | High Point Pharmaceuticals, LLC | Compounds active at the histamine H3 receptor |
CN101495184A (zh) | 2005-07-15 | 2009-07-29 | Amr科技公司 | 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用 |
CA2606004A1 (en) | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
AU2007229492B2 (en) | 2006-03-28 | 2011-11-03 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
CA2653062A1 (en) | 2006-05-23 | 2007-11-29 | Transtech Pharma, Inc. | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
ATE538116T1 (de) | 2006-05-29 | 2012-01-15 | High Point Pharmaceuticals Llc | 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
-
2006
- 2006-06-30 EP EP11176842A patent/EP2386554A1/en not_active Withdrawn
- 2006-06-30 WO PCT/EP2006/063753 patent/WO2007003604A2/en active Application Filing
- 2006-06-30 MX MX2007015675A patent/MX2007015675A/es active IP Right Grant
- 2006-06-30 EP EP06764002A patent/EP1902028A2/en not_active Withdrawn
- 2006-06-30 US US11/917,823 patent/US8501739B2/en not_active Expired - Fee Related
- 2006-06-30 AU AU2006264966A patent/AU2006264966B2/en not_active Ceased
- 2006-06-30 BR BRPI0613564-1A patent/BRPI0613564A2/pt not_active IP Right Cessation
- 2006-06-30 RU RU2011142654/04A patent/RU2499795C2/ru not_active IP Right Cessation
- 2006-06-30 CA CA002614116A patent/CA2614116A1/en not_active Abandoned
- 2006-06-30 AT AT10166493T patent/ATE536344T1/de active
- 2006-06-30 JP JP2008519917A patent/JP5121707B2/ja not_active Expired - Fee Related
- 2006-06-30 KR KR1020087000240A patent/KR101286569B1/ko not_active IP Right Cessation
- 2006-06-30 EP EP10166493A patent/EP2233470B1/en not_active Not-in-force
- 2006-06-30 ES ES10166493T patent/ES2375929T3/es active Active
- 2006-06-30 CN CN2012104648404A patent/CN103110635A/zh active Pending
-
2012
- 2012-05-15 US US13/472,090 patent/US8846677B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3886161A (en) * | 1970-12-14 | 1975-05-27 | Sandoz Ag | 2-Piperazino-3-cyano-5-phenyl-pyridines |
GB1345880A (en) * | 1971-06-18 | 1974-02-06 | Cepbepe | Pyridazine derivatives |
US4251658A (en) * | 1977-06-13 | 1981-02-17 | Richter Gedeon Vegyeszeti Gyar Rt. | 3-(1-Pyrazolyl)-pyridazine derivatives |
DE2824764A1 (de) * | 1978-06-06 | 1979-12-20 | Hoechst Ag | Neue pyridylpiperazinderivate und verfahren zu ihrer herstellung |
US4616014A (en) * | 1981-10-22 | 1986-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
EA005160B1 (ru) * | 2001-07-12 | 2004-12-30 | Ле Лаборатуар Сервье | НОВЫЕ СОЕДИНЕНИЯ ОКТАГИДРО-2H-ПИРИДО[1,2-α]ПИРАЗИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ИХ СОДЕРЖАЩИЕ |
WO2005028438A1 (ja) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
Non-Patent Citations (4)
Title |
---|
Contreras J.-M. et al. Journal of Medicinal Chemistry, 1999, vol.42, no.4, pp.730-741, tables. Parrot I et al, Synthesis, 1999, no.7, pp.1163-1168, table 2, compound 1. Klauschenz E et al, European Journal of Medicinal Chemitry, 1994, vol.29, no.3, pp.175-184, table 1, compound 61. Contreras J.-M. et al, Journal of Medicinal Chemistry, 2001, vol.44, no.17, pp.2707-2718, tables. Brown D. J. et al, Australian Journal of Chemistry, 1981, vol.34, no.11, pp.2423-2429, table 1. Database Beilstein, BRN 4870130 1991, abstract. Database Beilstein, BRN 6398075 1988, abstract. Coppola G.M. et al. Journal of Heterocyclic Chemistry, 1980, vo.17, no.7, pp.1479-1482, compound 7C. Werbel L.M. et al. Journal of Heterocyclic Chemistry, 1979, vol.16, no.5, pp.881-894, compounds 13, 22, 30, 32. Database Beilstein, BRN 4182175 1991, abstract. Database Beilstein, Citation No. 5688187, BRN 4807006 1989, abstract. Steck E.A. et al. Journal of Heterocyclic Chemistry, 1975, vol.12, no.5, pp.1009-1013, page 1011 * |
Kawaguchi K et al, European Journal of Pharmacology, 1999, vol.364, no.2-3, pp.99-105, compound BW619C89. Tafesse L et al, Bioogranic & Medicinal Chemistry Letters, 2004, vol.14, no.22, pp.5513-5519, scheme 2, compound 6. Haugwitz R.D. et al, Journal of Medicinal Chemistry, 1982, vol.25, no.8, pp.969-974, table 1, compound 16. Levay В et al. Journal of Physical Chemistry. A Molecules, Spectroscopy, Kinetics, Environment and General Theory, 2004, vol.108, pp.1753-1756, compound 3. Adam I et al, Synlett, 2004, no.11, pp.2031-2033, table 1, compound 6c, 6d. * |
Lumma W.C. et al. Journal of Medicinal Chemistry, 1978, vol.21, no.6, pp.536-542, table 1, compound 3p. * |
Rival Y et al. Journal of Medicinal Chemistry, 1998, vol.41, pp.311-317, compound 11. * |
Also Published As
Publication number | Publication date |
---|---|
EP2233470B1 (en) | 2011-12-07 |
ATE536344T1 (de) | 2011-12-15 |
EP1902028A2 (en) | 2008-03-26 |
MX2007015675A (es) | 2008-02-20 |
BRPI0613564A2 (pt) | 2011-01-18 |
US20090312309A1 (en) | 2009-12-17 |
AU2006264966B2 (en) | 2013-02-21 |
RU2011142654A (ru) | 2013-04-27 |
JP2009500372A (ja) | 2009-01-08 |
KR101286569B1 (ko) | 2013-07-23 |
KR20080032069A (ko) | 2008-04-14 |
US8846677B2 (en) | 2014-09-30 |
CA2614116A1 (en) | 2007-01-11 |
US8501739B2 (en) | 2013-08-06 |
EP2233470A1 (en) | 2010-09-29 |
ES2375929T3 (es) | 2012-03-07 |
CN103110635A (zh) | 2013-05-22 |
WO2007003604A2 (en) | 2007-01-11 |
WO2007003604A3 (en) | 2007-06-21 |
US20120232078A1 (en) | 2012-09-13 |
JP5121707B2 (ja) | 2013-01-16 |
EP2386554A1 (en) | 2011-11-16 |
AU2006264966A1 (en) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2499795C2 (ru) | Антагонисты гистаминовых н3-рецепторов | |
RU2433128C2 (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
JP2016512825A5 (ru) | ||
RU2389722C2 (ru) | Варианты имидазола в качестве модуляторов рецептора гамма-аминомасляной кислоты (gaba) для лечения желудочно-кишечных (жк) расстройств | |
RU2452738C2 (ru) | Соединения, модулирующие активность c-fms и/или c-kit, и их применения | |
RU2413726C2 (ru) | Замещенные биарильные аналоги пиперазинилпиридина, их применение в терапии, фармацевтическая композиция, фармацевтический препарат, способы уменьшения проводимости кальция и ингибирования связывания капсаициновых рецепторов | |
JP2014511869A5 (ru) | ||
RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
RU2427573C2 (ru) | Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1) | |
RU2008127491A (ru) | Применение антагониста cb1 для лечения побочных эффектов и негативных симптомов шизофрении | |
JP2016517878A5 (ru) | ||
NZ599778A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
RU2006137716A (ru) | Ингибиторы гистондеацетилазы | |
JP2009513575A5 (ru) | ||
JP2007534687A5 (ru) | ||
JP2013512900A5 (ru) | ||
UY29389A1 (es) | Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones. | |
EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
RU2372348C2 (ru) | Производные индолилмалеимида в качестве ингибиторов ркс | |
JP2009516685A5 (ru) | ||
RU2005109561A (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
NZ591427A (en) | P38 map kinase inhibitors | |
RU2016136116A (ru) | Фармацевтические соединения | |
RU2005121897A (ru) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160701 |